Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05857969 · ClinicalTrials.gov registry record · Phase 1
Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling
A Phase 1 study of Recurrent Childhood Acute Lymphoblastic Leukemia and Recurrent Childhood Rhabdomyosarcoma, sponsored by Florida International University.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 65
- Enrollment target
- 1
- Study location
NCT05857969 is a Phase 1 study of Recurrent Childhood Acute Lymphoblastic Leukemia and Recurrent Childhood Rhabdomyosarcoma that is actively recruiting participants, run by Florida International University. The registered enrollment target is 65 participants, below the 121-participant average among 11 other Recurrent Childhood Acute Lymphoblastic Leukemia trials with a reported enrollment target (46% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05857969, a Phase 1 study of Recurrent Childhood Acute Lymphoblastic Leukemia and Recurrent Childhood Rhabdomyosarcoma, is actively recruiting participants, sponsored by Florida International University.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 65 participants
- Enrollment target
- 1
- Study location
Study Summary
Functional precision medicine (FPM) is a relatively new approach to cancer therapy based on direct exposure of patient- isolated tumor cells to clinically approved drugs and integrates ex vivo drug sensitivity testing (DST) and genomic profiling to determine the optimal individualized therapy for cancer patients. In this study, we will enroll relapsed or refractory pediatric cancer patients with tissue available for DST and genomic profiling from the South Florida area, which is 69% Hispanic and 18% Black. Tumor cells collected from tissue taken during routine biopsy or surgery will be tested.
Conditions Studied
Interventions
- DEVICE Functional Precision Medicine
Study Locations (1)
Florida
- Nicklaus Children's Hospital - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2023-02-22 |
| Est. Completion | 2028-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05857969
The ClinicalTrials.gov registry entry for NCT05857969 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 65 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 121-participant average among 11 other Recurrent Childhood Acute Lymphoblastic Leukemia trials with a reported enrollment target (46% lower). The listed sponsor is Florida International University, which has 89 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Recurrent Childhood Acute Lymphoblastic Leukemia appearing as the primary indexed condition, and to 1 intervention - of which Functional Precision Medicine is the first listed.
NCT05857969 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT05857969 about?
NCT05857969 is a clinical study titled "Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling". Functional precision medicine (FPM) is a relatively new approach to cancer therapy based on direct exposure of patient- isolated tumor cells to clinically approved drugs and integrates ex vivo drug sensitivity testing (DST) and genomic profiling to determine the optimal individualized therapy for ca...
What is the current status of trial NCT05857969?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 65 participants. The study started on 2023-02-22. Estimated completion is 2028-12-31.
What conditions does trial NCT05857969 study?
This clinical trial studies the following conditions: Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Rhabdomyosarcoma, Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Soft Tissue Sarcoma, Recurrent Childhood Large Cell Lymphoma.
What interventions are being tested in trial NCT05857969?
The interventions under investigation include: Functional Precision Medicine (DEVICE).
Who is sponsoring clinical trial NCT05857969?
This trial is sponsored by Florida International University, which has 89 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05857969 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Childhood Acute Lymphoblastic Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
RECRUITING · Phase 1
-
Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults w/ Recurrent or Refractory B Cell Malignancies
ACTIVE NOT RECRUITING · Phase 1
-
Temsirolimus, Dexamethasone, Mitoxantrone Hydrochloride, Vincristine Sulfate, and Pegaspargase in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma
COMPLETED · Phase 1
-
Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
COMPLETED · Phase 1
-
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
COMPLETED · Phase 1
-
Chemoimmunotherapy With Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL)
COMPLETED · Phase 1
Explore more on PlainTrial
Recurrent Childhood Acute Lymphoblastic Leukemia
All registered trials for this condition
Recurrent Childhood Rhabdomyosarcoma
All registered trials for this condition
Florida
All trials with a study site in Florida
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.